Clinuvel Pharmaceuticals Limited

CLINUVEL said sales revenue increased 4% year over year to just under $37 million, marking its highest first-half sales result. Interest income rose 14% to $5.3 million, helped by larger cash reserves and average term-deposit yields of about 4.5% across roughly 300 days. Cash reserves increased by $9 million to just under $233 million; net assets increased by $8.2 million to just under $250 million; and the company remained debt-free for the 21st consecutive year. Management said expenses were up 22% for the period, with personnel expenses up 16%, commercial distribution up 42%, finance/corporate/legal up 47%, and other expenses up 191% due largely to R&D programs. Philippe Wolgen said full-year expense guidance remains about $55 million to $58 million excluding capital expenditures. No explicit EPS or gross margin figure was stated. Forward-looking items discussed included vitiligo CUV105 top-line results in the second half of 2026, the start of CUV107, preclinical peptide formulation results later this year, and completion of the ADR/NASDAQ listing process.

Philippe Wolgen framed the quarter as part of a deliberate, long-term strategy built on tight financial control, gradual expansion, and optionality. He said the company intentionally increased spending on R&D, vitiligo, regulatory work, and its peptide platform, and that management is comfortable because it remains in line with plan and supported by positive cash flow. He emphasized that CLINUVEL is aiming to build a sustainable, diversified, multi-billion-dollar enterprise and said cash is what gives the business optionality.

Peter Vaughan highlighted stable, consistent results, with revenue up 4% and expense growth driven by expansion initiatives rather than inefficiency. He pointed to record first-half sales, 20 consecutive profits, and cash rising to just under $233 million, with net assets at just under $250 million; he also said the company has no debt and no equity dilution since March 2016. He explained that investment income benefited from term deposits at about 4.5% yield, while other income reflected a non-cash foreign-currency translation loss. He also noted that the company is spending on in-house capabilities, regulatory work, and manufacturing, with full-year expense guidance of $55 million to $58 million excluding capex.

Analysts focused heavily on vitiligo timing, asking whether CLINUVEL can file before both CUV105 and CUV107 are complete; management said no, the plan is to finish both studies before filing, with EMA first and FDA second. Questions also covered the ACTH/NEURACTHEL program, where Philippe said Europe first via mutual recognition should help accelerate the later U.S. path. On EPP, management said Medicaid exposure is below 5% of U.S. patients and therefore Medicaid cuts should have little impact, while also addressing the FDA’s rejection of Disc Medicine’s Bitopertin by arguing it underscored CLINUVEL’s safer, already-approved position in EPP. Analysts also asked about the Nasdaq ADR listing and revenue regional mix; Peter said reporting frequency will not change, and that the U.S. revenue softness was mainly due to the government shutdown delaying reimbursements and Medicare processing.